View Older Stories View More Recent Stories
-
Roth Capital Confident in Full Sarilumab Approval; Affirms Regeneron (REGN) at 'Buy'
-
Quantenna Communications (QTNA) IPO Opens at $16.80/Share
-
Quantenna Communications (QTNA) Prices 6.7M Common Stock IPO at $16/Share, at Upper-End of Expected Range
-
Quantenna Communications, Inc. Announces Pricing of Initial Public Offering
-
Roth Capital Confident in Improving FY17 Visibility for Ballard Power (BLDP); Reaffirms at 'Buy'
-
Notable Analyst Rating Changes 10/27: (NOW) (AVY) (GRUB) Upgraded; (ETR) (PB) (SNI) Downgraded
-
Roth Capital Upgrades PCM, Inc (PCMI) to Buy
-
Biocept Appoints David Moskowitz Vice President, Strategy & Corporate Communications
-
Roth Capital Upgrades GrubHub Inc. (GRUB) to Buy
-
BTIG Builds Out Equity Research Group with Biotechnology Analyst Robert C. Hazlett, III
-
MeetMe's (MEET) Price Target Raised to $9.25 at Roth
-
Roth Capital Downgrades FuelCell Energy (FCEL) to Neutral on Beacon Falls Miss
-
Streetinsider.com's Hot Lunchtime Reads 10/24: (ADRO) (AMTD) (TWTR) (INO)
-
Roth Capital Affirms Bioblast Pharma (ORPN) at 'Buy'; Sees Trehalose PK Data as 'Meaningful'
-
Roth Capital Trims PT on Aduro Biotech (ADRO) to $20 Amid FDA Partial Hold on LADD Trials
-
Notable Analyst Rating Changes 10/21: (CHK) (NRF) (AVT) Upgraded; (MEMP) (YHOO) (WWAV) Downgraded
-
Northwest Biotherapeutics (NWBO) Enters $5M Common Stock Registered Direct Offering
-
NW BIO Announces Registered Direct Offering
-
Roth Capital Starts Asure Software (ASUR) at Buy
-
Roth Affirms Applied Genetic Tech (AGTC) at 'Neutral' Amid CNGA3 IND Filing; Application Expands Present Pipeline
-
Biocept Announces Closing of $10 Million Public Offering of Common Stock and Warrants
-
Ocean Power Technologies, Inc. Announces Closing of Common Stock Offering
-
Roth Capital Keeps Cerulean Pharma (CERU) at 'Buy' Amid Capital Raise, Key Collaboration with Novartis
-
Roth Capital Would be Buyers of Cree (CREE) on Turnaround; Affirms at 'Buy'
-
Roth Capital Resumes Acadia Pharmaceuticals (ACAD) at Neutral
-
Nektar Therapeutics (NKTR) Prices 13M Common Stock Offering at $13.50/Share
-
Nektar Therapeutics Prices Public Offering of Shares of Common Stock
-
Streetinsider.com's Hot Lunchtime Reads 10/18: (NKE) (ATNM) (TTWO) (KMX)
-
Roth Capital Remains Positive on Actinium Pharma (ATNM) as Iomab-B Gains Orphan Designation in Europe
-
Roth Affirms Cytokinetics (CYTK) at 'Buy' Following Enrollment of First VIGOR-ALS Patient
-
Capstone Turbine (CPST) Prices $7.5M Offering of Common Stock and Warrants
-
Capstone Turbine Corporation Announces Pricing of $7.5 Million Offering of Common Stock and Warrants
-
PlacementTracker Publishes Q3 2016 Private Placement Market League Tables
-
Quantenna Communications Launches Initial Public Offering
-
Unusual 11 Mid-Day Movers 10/14: (CTRV) (FBMS) (MGT) Higher; (OPTT) (TAYD) (BIOC) Lower
-
Roth Capital Downgrades Fenix Parts (FENX) to Neutral
-
Ocean Power Technologies (OPTT) Prices 2.4M Common Stock Offering at $2.75/Share
-
Ocean Power Technologies, Inc. Announces Pricing of Common Stock Offering
-
Ocean Power Technologies (OPTT) Prices 2.4M Common Stock Offering at $2.75/Share
-
Biocept (BIOC) Prices 9.1M Share Common Stock Offering for Proceeds of $10M
-
Biocept Announces Pricing of $10 Million Public Offering of Common Stock and Warrants
-
Streetinsider.com's Hot Lunchtime Reads 10/13: (TWTR) (ESPR) (SSYS) (APTO)
-
Roth Capital Affirms Aptose Biosciences (APTO) at 'Buy'; Clinical Hold Update Disappointing, But Positives Remain
-
TG Therapeutics (TGTX) Remains 'Focus Pick' Selection at Roth Capital Amid Amended GENUINE Phase 3
-
PIPE Deals Rise 38% in Q3 2016
-
ROTH Capital Partners Releases its 2016-2017 Millennial Mom Survey
-
Roth Capital Starts Remark Media (MARK) at Buy
-
Azure Power Global (AZRE) IPO Opens Lower
-
Azure Power Global Limited Announces Pricing of its Initial Public Offering
-
Roth Capital Affirms JinkoSolar (JKS) at 'Neutral'; Says Downstream Business 'Finally' Being Monetized

